AI-Assisted Treatment Planning: What Case Acceptance Data Actually Shows

The headline: modest, real improvements, not transformation

AI treatment planning tools are showing case acceptance lifts in the 3–8% range for practices that implement them properly. That's meaningful. It's not revolutionary.

These numbers come from a mix of vendor-published outcome studies and practitioner-reported data. The variance matters because it tells you something important: implementation, staff buy-in, and patient communication style move the needle more than the AI itself.

What the published data actually says

Overjet published a 2024 case study involving 12 participating practices tracking case acceptance over a 6-month period. The reported average lift was 5.2% when radiographic findings were presented using AI-generated treatment plans versus provider-only narratives. Sample size was small, and results weren't randomized, so take that framing into account.

Diagnocat reported similar territory in a 2023 retrospective analysis of practices using their platform: practices tracking acceptance rates showed a mean improvement of 4.8% in comprehensive treatment plan acceptance in the first year of use. Again—this is vendor-published data, meaning selection bias exists (successful implementations may be overrepresented).

Independent research is thinner on the ground. A 2024 survey by the American Dental Association (per ADA Health Policy Institute reporting) found that 34% of practices using AI diagnostic or planning tools reported improved patient communication about treatment options, but the survey did not isolate case acceptance as a standalone metric. Communication improvement does not automatically convert to acceptance improvement.

Why the gap between promise and practice?

Three things matter more than the tool.

First: staff training and adoption. A practice that deploys Pearl or another planning AI without training hygienists and front desk staff to present findings differently will see minimal lift. The AI generates better visual communication—but only if someone actually uses it in the patient conversation. Practices reporting higher acceptance gains (6–8% range) consistently cite front-office and clinical staff training as a prerequisite.

Second: patient expectation setting. Showing a digital treatment plan on a screen does not increase acceptance if the patient arrived expecting a cleaning and a recall. Practices that see stronger lifts use AI-assisted plans to segment patients into consultation-worthy cases earlier in the funnel, not just to convert existing resistance. That's a workflow change, not a technology change.

Third: baseline acceptance rates matter. A practice starting at 65% acceptance will see different absolute gains than one starting at 45%. The data does not consistently control for baseline, so a 5% lift at 65% acceptance (to 70%) is a different operational story than 5% at 45% (to 50%).

What doesn't show up in case acceptance numbers

This matters for ROI calculations: AI treatment planning tools are often justified only on case acceptance improvement, which undersells their utility.

Practices report measurable value in treatment plan documentation. Using Bola AI or similar platforms creates a timestamped, AI-assisted clinical record that improves consistency, reduces liability exposure, and makes associate performance evaluation more objective. That's not captured in case acceptance data, but it's real operational value.

Time savings in plan generation are also real but often overstated. Most AI planning tools reduce chairside or operatory time by 8–15 minutes for complex cases. Scale that across a schedule and it's meaningful. But it's rarely the primary driver of adoption—practices adopt these tools thinking case acceptance, then discover time and consistency benefits as secondary wins.

The practices that see bigger lifts

Who's in the 7–8% range? Patterns emerge:

• DSOs and larger groups with standardized patient communication protocols. They can train staff systematically and measure results across multiple locations.
• Practices doing high-case-value treatment. Implants, cosmetics, ortho-integrated work. A 5% acceptance lift on $8k cases moves revenue differently than on $1.5k cases.
• Practices with existing low acceptance rates. Counterintuitively, struggling practices sometimes see bigger relative gains because the baseline is so low that any communication improvement compounds.
• Practices using AI planning with other patient communication tools. Weave users combining AI plans with automated follow-up messaging, or NexHealth users integrating plan presentation into scheduling workflows, report higher adoption and acceptance.

The implementation reality check

According to practitioner feedback collected across forums and DSO operations groups, the most common outcome is this: first-year adoption shows 2–4% acceptance lift. By year two, practices that invest in staff training and workflow integration see that drift toward 5–6%. Practices that don't invest actively in training see the tool become a nice feature that's inconsistently used.

Cost of entry matters for ROI. Monthly SaaS tools like Pearl or Diagnocat run $400–800/month for a solo practice. A 5% acceptance lift on a $2M annual production practice is roughly $100k in gross revenue gain (assuming average case value in the $5–6k range). That pencils out. Smaller practices or those with lower acceptance-rate-sensitive revenue need to be honest about whether the math works.

What's overstated

Vendors sometimes conflate case presentation improvement with case acceptance. Patients may engage more with a visual plan and ask better questions. That's real. But asking questions doesn't mean accepting. Some practices see improved communication satisfaction without acceptance lift—and that's valuable for retention and referrals, just not the metric being promised.

Also: the data does not show that AI planning drives upselling or plan complexity inflation. Some practices worry that AI will push them toward recommending more aggressive treatment. The available data suggests the opposite—practices tend to use AI as a documentation and communication tool, not as a clinical decision amplifier. Your clinical judgment remains your clinical judgment.

The bottom line

AI-assisted treatment planning works. The acceptance lift is real but incremental. Expect 3–8%, with 5% as a reasonable middle ground if you implement properly. Don't adopt on case acceptance lift alone. Justify it on documentation, consistency, time savings, and patient communication—those are the stable wins. If case acceptance improves, that's the bonus.

The practices getting the most value are those treating it as a workflow upgrade, not a silver bullet.